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Estrogen receptors and function in 
the male reproductive system
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AbstrAct
A substantial advance in our understanding on the estrogen signaling occurred in the last deca-
de. Estrogens interact with two receptors, ESR1 and ESR2, also known as ERα and ERβ, respec-
tively. ESR1 and ESR2 belong to the nuclear receptor family of transcription factors. In addition 
to the well established transcriptional effects, estrogens can mediate rapid signaling, triggered 
within seconds or minutes. These rapid effects can be mediated by ESRs or the G protein-cou-
pled estrogen receptor GPER, also known as GPR30. The effects of estrogen on cell proliferation, 
differentiation and apoptosis are often mediated by growth factors. The understanding of the 
cross-talk between androgen, estrogen and growth factors signaling pathways is therefore es-
sential to understand the physiopathological mechanisms of estrogen action. In this review we 
focused on recent discoveries about the nature of the estrogen receptors, and on the signaling 
and function of estrogen in the male reproductive system. Arq Bras Endocrinol Metab. 2009;53(8):923-33
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resumo
Durante a última década, ocorreu um avanço substancial no conhecimento da sinalização do es-
trógeno. Estrógenos interagem com dois receptores, ESR1 e ESR2, também conhecidos como 
ERα e ERβ, respectivamente. ESR1 e ESR2 pertencem à família de receptores nucleares, que 
funcionam como fatores de transcrição. Além dos bem estabelecidos efeitos transcricionais, 
os estrógenos medeiam a sinalização rápida, desencadeada dentro de segundos ou minutos. 
Esses efeitos rápidos podem ser mediados por ESRs ou pelo receptor de estrógeno acoplado à 
proteína G, GPER, também conhecido como GPR30. Os efeitos de estrógenos sobre a prolifera-
ção celular, diferenciação e apoptose são, muitas vezes, mediados por fatores de crescimento. 
Portanto, a compreensão da interação entre as vias de sinalização de andrógeno, estrógeno e 
fatores de crescimento é essencial para entender os mecanismos fisiopatológicos envolvidos 
na ação estrogênica. Nesta revisão, foram abordadas descobertas recentes sobre a estrutura 
dos receptores, a sinalização e a função do estrógeno no sistema reprodutor masculino. Arq Bras 
Endocrinol Metab. 2009;53(8):923-33
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IntroDuctIon
Estrogens play key roles in the development and maintenance of reproductive function and fertility 
(1-4). Estrogens also have an important role in patho-
logical processes observed in tissues of the reproducti-
ve system (5,6). In addition, they exert a vast range of 
biological effects in the cardiovascular, musculoskeletal, 
immune, and central nervous systems (1). The most 
potent estrogen produced in the body is 17β-estradiol 
(E2). Although estrone and estriol, two E2 metabolites, 
bind to estrogen receptors (ESRs) with high-affinity, 
they are much weaker agonists compared to E2.
In this review, we have described briefly (i) the struc-
ture and signaling pathways of ESRs and (ii) the lo-
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calization and function of ESRs in organs of the male 
reproductive system.
Estrogens are synthesized from androgens by the 
aromatase complex, which contains the cytochrome 
P450 enzyme encoded by the CYP19 gene (7). Aro-
matase expression is detected in Sertoli-Leydig cells, 
spermatogonia, spermatocytes, elongate spermatids 
and spermatozoa in adult mice and rats (7), and in Ser-
toli-Leydig cells, spermatocytes, spermatids and sper-
matozoa in man (4). Moreover, aromatase has been 
immunolocalized in epithelial cells of human efferent 
ducts and in the proximal caput of the epididymis and 
in rat epididymis (4,7,8), suggesting additional sources 
of estrogen in the male reproductive system and the 
possibility of paracrine/autocrine effects.
The crucial role of estrogen for the reproducti-
ve function has been demonstrated by studies with 
mice with targeted disruption of ESRs (Esr1-/-, Esr2-/-, 
Esr1-/-/Esr2-/-), aromatase enzyme (Cyp19-/-), and ani-
mals treated with the antiestrogen (ICI 182,780) (9-
12). The studies with knockout animals have shown 
that the spermatogenesis, steroidogenesis and fertility 
of Esr1-/-, Esr1-/-/Esr2-/- and Cyp19-/- animals are affec-
ted (9,10), but none of these parameters is affected in 
Esr2-/- animals (10). However, all these Esr2 mutants 
displayed alternative splicing transcripts. A recent study 
showed that a new Esr2-/- mouse mutant, in which exon 
3 of Esr2 was deleted by Cre/LoxP-mediated excision, 
was completely devoid of any downstream transcripts, 
and the males were also sterile (12). The origin for the 
sterility of these male mice is unknown, because their 
gonads and internal genital organs are histological nor-
mal and the mobility of their spermatozoa appears also 
normal (12). It is possible that the efferent ductules, 
epididymis and/or prostate, which all express ESR2 
in the WT mice, may not be fully functional in mouse 
Esr2-null mutant.
estrogen receptors: structure AnD 
sIgnAlIng pAthwAys
Cellular signaling of estrogens is mediated through two 
ESRs, ESR1 and ESR2 (also known as ERα and ERβ, 
respectively), both belonging to the nuclear receptor 
family of transcription factors (13,14). ESRs contain 
conserved structure and five distinct functional do-
mains (1,13,14). The N-terminal A/B domain is the 
most variable region, and the human ESR1 and ESR2 
share less than 20% amino acid identity, indicating that 
this domain may contribute to ER subtype-specific ac-
tions on target genes. This region contains an activation 
function (AF-1) that is ligand-independent and shows 
promoter- and cell-specific activity. The C-domain is the 
DNA-binding domain (DBD), and features two zinc-
finger motifs, which are not only responsible for DNA-
binding, but also for dimerization of the receptors, allo-
wing the formation of homo- and heterodimers. This 
domain is highly conserved between ESR1 and ESR2 
(95% amino acid identity), and the DBD from both 
receptors bind to the same estrogen response element 
(ERE). The D-domain is a flexible hinge between the 
DBD and the ligand-binding domain (LDB). This do-
main, which is not well conserved between ESR1 and 
ESR2 (only 30% amino acid identity), contains a nucle-
ar localization signal, important for nuclear transloca-
tion. ESR1 and ESR2 share approximately 55% amino 
acid identity in LBD. The LBD is important for ligand 
binding and receptor dimerization and contains a hor-
mone-dependent activation function (AF-2). Both AFs 
recruit a range of coregulatory protein complexes to the 
DNA-bound receptor. The LBDs of ESR1 and ESR2 
have very similar three-dimensional structures. Howe-
ver, the amino acids lining the ligand-binding cavities 
of ESR1 and ESR2 differ in two positions. Further-
more, ligand-binding cavity of ESR2 is approximately 
20% as large as the one from ESR1, and this may have 
implications for the selective affinity and pharmacology 
of ligands. The F-domain is less conversed between the 
two ESRs (less than 20% amino acid identity), and the 
functions of this domain remain undefined.
ESR1 and ESR2 are encoded by two different genes 
located on different chromosomes. Several splice va-
riants have been described for these receptors, but whe-
ther all the variants are expressed as functional proteins 
is not clear (13,14). Multiple RNA splicing variants 
for ESR1 have been reported in humans (13,14). Full-
length human ESR1 is 595 long amino acids, and both 
short ESR1 isoforms, hESR1-46 and hESR1-36, lack 
the N-terminal region containing AF-1. The hESR1-
36 lacks both transcriptional activation domains and 
contains an exon coding for myristoylation sites, thus 
predicting an interaction with the plasma membrane. 
The hESR1-46 antagonizes the proliferative actions of 
the hESR1-66 in MCF-7 breast cancer cells. In the rat 
pituitary gland, an ESR1 variant named TERP-1 (trun-
cated ER product-1) is expressed in the lactotrope cells.
The full-length human ESR2 is 530 long amino 
acids and the rat and mouse ESR2 is 549 amino acids 
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(Esr2_v1 isoform). Four alternative ESR2 isoforms have 
been described in humans, and many of these are ex-
pressed as proteins. The mouse and rat Esr2_v2 contains 
an 18-amino acid insertion in the LBD that causes a 
significant decrease in binding affinity. Deletion of exon 
3 results in rat isoforms unable to bind to DNA (13), 
and the deletion of exon 5 and/or 6 in mice results in 
isoforms lacking various parts of the LBD. ESR2 isofor-
ms can differentially modulate estrogen signaling and, 
as a consequence, impact target gene regulation (13).
The classical mechanism of ESR action involves E2 
binding to receptors located in the nucleus. After bin-
ding estrogen, ESR dissociates from its chaperone pro-
teins, phosphorylates, and dimerizes. Hormone binding 
also induces a conformational change within the ligand 
binding domain of the receptors, and this conforma-
tional change allows coactivator proteins, for example, 
amplified in breast cancer-1 (AIB1), nuclear-receptor-
coactivator-1 (NCoA-1/SRC1) and the p300 and 
CBP-associated factor (PCAF), to be recruited. These 
activated ESR-dimer complexes bind to specific EREs 
located in the promoters of target genes (1,14,15).
In humans, around one third of the genes that are 
regulated by ESRs do not contain ERE-like sequences 
(15,16). This mechanism of ERE-independent ESR 
activation is postulated to involve a tethering of the 
ligand-activated ESR to other transcription factors that 
are directly bound to DNA via their respective respon-
se elements. Several genes are activated by E2 through 
the interaction of ESRs with Fos and Jun proteins at 
activating protein-1 (AP-1) binding sites to induce or 
regulate transcriptional activity. Genes that contain 
GC-rich promoter sequences are regulated in a similar 
manner through the interaction of ESRs with the Sp-1 
transcriptional factor. Other transcriptional factors are 
also involved, such as nuclear factor kB (NF-kB) and 
signal transducer and activator of transcription (STAT) 
five binding sites. The actions of E2-ESRs-transcription 
factors depend on the ligand, the cell type, and the re-
ceptor subtype (15,16).
In addition to the well-established transcriptional 
effects of E2 mediated by the classical nuclear ESRs 
(13-15), estrogen also mediates rapid effects, occur-
ring within seconds or minutes. These rapid effects 
include activation of different downstream signaling 
pathways, for example, the mitogen-activated protein 
kinases (MAPKs) and phosphatidylinositol 3-kinase 
(PI3K) pathways, which, in turn, can modulate nucle-
ar transcriptional events and cell proliferation (15,17). 
Nevertheless, recent studies have revealed the contribu-
tion of a novel ESR, namely GPER (G protein-coupled 
ESR, or GPR30), which belongs to the family of seven-
transmembrane G protein-coupled receptors (GPCRs). 
The activation of this receptor also induces activation 
of different downstream signaling pathways. Other 
compounds, besides estrogen, may also activate GPER: 
ESR antagonists, such as fulvestrant (ICI 182,780), 
and G-1, which is a GPER agonist (18,19). GPER has 
been identified in a variety of human and rodent estro-
gen target tissues (18,19).
We summarized the data about ESRs localization 
and function in some components of the male repro-
ductive system.
testis
In testis from immature and adult rats, splicing variants 
for Esr1 were not detected, and only a single protein 
band for ESR1 was detected (20). On the other hand, 
two splicing variants were detected for Esr2 in testis: 
the Esr2_v1 isoform (20), with high similarity with the 
human ESR2 (21), and the Esr2_v2, which contains an 
in-frame insert of 54 nucleotides, only described in tis-
sues from rodents (13). Esr2_v2 encodes a protein that 
differs from the isoform 1 of ESR2 only by an inser-
tion of 18 aminoacids in the ligand binding domain. 
In fact, in Western blot analysis only one protein band 
was distinguished with an antibody that recognizes the 
aminoterminal region of the receptor that is common 
to both ESR2 isoforms (20). The physiological implica-
tion of the existence of several ESR2 isoforms has been 
investigated. The human ESR2 isoform 1 apparently is 
the only fully functional. However, the other isoforms 
can heterodimerize with ESR2 isoform 1 under the sti-
mulation of estrogens and enhance the transactivation 
(13). Furthermore, the human ESR2 isoform 2 has 
been proposed to act as a dominant negative receptor, 
preventing estrogen action in gonocytes (22). The di-
fferential distribution of ESR2 variants in human testi-
cular cells may indicate that these variants have specific 
functions in spermatogenesis (23). On the other hand, 
the rodent ESR2 isoform 2 seems to be functional, 
although much higher concentrations of estrogen are 
required for its activity (13). A recent study reported 
the presence of the ESR2 isoforms 1 and 2 in human 
seminoma, in embryonal carcinoma and in their adja-
cent intratubular germ cells (24). This study suggests 
that both isoforms can mediate estrogen action in early 
and late neoplastic testicular germ cells.
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The expression of ESR1 and ESR2 in the fetal testis 
occurs very early in the development, and their distri-
bution in the different testicular cells has been exten-
sively studied in mammals (25). Immunohistochemical 
data have shown that ESR1 is present in the undifferen-
tiated gonad and in the fetal Leydig cells until birth in 
rodents (2). The presence of ESR1 is also detected in 
Sertoli cells from immature and adult rats (20). Althou-
gh germ cells from immature rats are ESR1-negative, 
some spermatids were positive for this receptor in the 
adult animal (20). On the other hand, the expression of 
ESR1 in human testis is controversial (3). While some 
authors did not find significant expression of ESR1 in 
human testis (26), others have found ESR1 in Leydig 
cells (27) and in human Leydig cell tumor (28). Inde-
ed, the presence of ESR1 in rat and human spermato-
zoa has been reported (4).
Our laboratory detected ESR2 specific immunostai-
ning in multiple cell types in rat testis, including Serto-
li-Leydig cells, and in some, but not all, germ cells (20), 
confirming previous studies. In humans, ESR2, but not 
ESR1 and androgen receptor (AR), is expressed in go-
nocytes and spermatogonia (29). It is worth to men-
tion that ESR2 is coexpressed with ESR1 in tumoral 
seminoma cells, where it may counteract the tumor cell 
proliferation mediated by ESR1 (30).
The role of estrogens in male reproduction is com-
plex. Estrogens have been suggested to control Leydig 
cell function at various stages of development. Prenatal 
estrogen treatment affected the differentiation of fetal 
Leydig cells (31), and the regeneration of Leydig cells 
is inhibited by estrogen in a rat model mimicking post-
natal Leydig cell development (32). Several studies also 
indicated a role for E2 as a paracrine/autocrine factor 
in the regulation of steroidogenesis in the Leydig cells 
from rodents (33). A recent study has demonstrated 
that the chronic imbalance of the androgen-estrogen 
ratio in the aromatase transgenic animal leads to severe 
abnormalities in the development, structure, and func-
tion of mouse Leydig cells, and these effects seem to be 
mediated by ESR1 (34).
Our laboratory detected, by immunofluorescence, 
the presence of ESR1 and ESR2 in the nuclei of Ser-
toli cells obtained from 15-day old rats (20). In cul-
tured Sertoli cells, a physiological concentration of E2 
activates a Src-mediated translocation of ESRs to the 
plasma membrane, which results in the activation of 
EGFR (epidermal growth factor receptor) and Erk1/2 
(extracellular-regulated kinase 1/2). Moreover, activa-
tion of ESR1 and/or ESR2 by E2 is also involved in 
proliferation of immature Sertoli cells (20). In fact, es-
trogen affects Sertoli cell proliferation (2,20) and may 
suppress differentiation (2), and 5α-androstane-3β, 
17β-diol (3βAdiol) is a potent modulator of ESR2-
mediated gene transcription in Sertoli cell lines (35). 
A recent study using estrogen non-responsive ESR1 
knock-in (ENERK1) mice, which have a point muta-
tion in the LBD of ESR1 that significantly reduces in-
teraction with and response to endogenous estrogens, 
but does not affect activation of ESR1 by growth fac-
tors, showed that estrogen-dependent ESR1 signaling 
is required for germ cell viability, most likely through 
support of Sertoli cell function (36). No changes are 
observed in the number of Sertoli cells and spermato-
gonia in the Esr1-/- mice (9). However, spermatogenesis 
arrest occurs in Esr1-/- mice (9), suggesting that Sertoli 
cell support of germ cell development through uniden-
tified ESR1-mediated mechanisms, may be through 
activation of growth factors. Studies with the mouse 
spermatogonial GC-1 cell line showed that E2 rapidly 
activates the EGFR/Erk/fos pathway through a cross-
talk between GPER and ESR1, leading to cell prolifera-
tion (37). In cultured Sertoli cells obtained from 15-day 
old rats, GPER participates in E2 rapid actions and may 
regulate apoptosis (our unpublished data). ESRs and/
or GPER may mediate 17β-estradiol actions important 
for Sertoli cell function and maintenance, consequently 
affecting spermatogenesis and male (in)fertility.
Estrogens also affect directly male germ cells and 
regulate storage and phosphorylation of Fos proteins 
in the cytoplasm and nucleus of germ cells, respectively, 
indicating that estrogen may be involved in the mecha-
nisms inducing spermatogonial proliferation (38). Re-
cent studies have shown that E2 and 3βAdiol, an ESR2 
selective ligand, stimulate spermatogonial deoxyribo-
nucleic acid synthesis in rat seminiferous epithelium 
in vitro (39), and low doses of bisphenol A stimulate 
human seminoma (JKT-1) cell proliferation by allo-
wing a rapid membrane-initiated activation of cAMP-
dependent protein kinase (PKA) and cGMP-dependent 
protein kinase (PKG) signaling pathways associated 
with phosphorylation of the transcription factor cAMP 
response-element binding protein (CREB) and the cell 
cycle regulator retinoblastoma protein (Rb) (40). 
In conclusion, ESRs and GPER may mediate 
17β-estradiol actions important for the function and 
maintenance of testicular cells, consequently affecting 
spermatogenesis and male (in)fertility.
Estrogen in the male reproductive system
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efferent ductules
The efferent ductules present the highest levels of ESRs 
ESR1 and ESR2 in the male reproductive system, and 
represent a major target of estrogen action. In mice and 
rats, ESR1 and ESR2 are expressed abundantly in cilia-
ted and non-ciliated cells of the efferent ductule epi-
thelium (41). In rats, ESR2 is also found in peritubular 
and some stromal cells (41). 
The efferent ductules connect rete testis to epidi-
dymis. Great part of the head of the epididymis in man 
and other mammals, but not in rodents, contains these 
ducts, and it was first thought that the efferent ductules 
would only transport sperm from testis to the epididy-
mis. However, the efferent ductules are now recogni-
zed as the main place of absorption of the fluid from 
the rete testis, an event that is crucial to concentrate 
sperm prior to entering the epididymal lumen (3). 
The primary mechanism involved in the movement 
of fluid in the ductules is the water transport and the 
active transport of ions (42-44). Studies in different 
species have demonstrated that 50 to 96% of the fluid 
secreted by the seminiferous tubules is reabsorbed by 
the epithelial cells of the efferent ductules (3). Some 
proteins involved in the reabsorption of the fluid have 
also been identified, such as the Na+-K+-ATPase, the 
aquaporins, AQP1 and AQP9, and the carbonic ani-
drase II (42-44).
The efferent ductules also absorb approximately 50 
to 90% of the total proteins that leave the testis (45,46). 
This process occurs by absorption or receptor-mediated 
endocytosis, the main mechanism involved in the cap-
ture of large molecules from the testicular fluid (46). 
The androgen binding protein (ABP) and the sulpha-
ted glycoprotein 2 (SGP-2) are examples of proteins 
absorbed by the efferent ducts epithelium (47,48). 
Some of the proteins secreted by the epithelial cells of 
the efferent ductules have already been identified, such 
as the saposin 1 (SGP-1) and the pro-enkephalins (49). 
Estrogen plays a crucial role regulating the ability 
of the efferent ductules to reabsorb the testicular fluid 
and to influence the seminal fluid composition. The 
most severe histopathological changes after disruption 
of ESR1 occur in this organ. The lack of ESR1 severely 
impairs the absorptive function of the efferent ductules, 
causing fluid accumulation and luminal dilation. The 
rete testes of the Esr1-/- were also dilated and protruded 
into the testis. Treatment of rats with fulvestrant (ICI 
182,780), an antiestrogen that impairs estrogen action 
on ESR1 and ESR2, cause morphological and func-
tional changes in the efferent ductules similar to those 
seen in the Esr1-/- mice (11), including luminal dila-
tion and reduction of the epithelial height (Figure 1A 
and B). On the other hand, treatment of rats with the 
aromatase inhibitor anastrozole does not seem to alter 
significantly the morphology of the efferent ductules 
(Figure 1C and D), and aromatase knockout animals 
do not present a significant morphological alteration of 
the efferent ductules (50). Combined with the results 
obtained with the ESR1 knockout animals, these re-
sults indicate that the presence of a functional ESR1 is 
mandatory to maintain the morphology and function 
of the efferent ductules. 
Studies with Esr1-/- and ICI 182,780-treated mice 
demonstrated that estrogen regulates the mRNA levels 
of several proteins involved in ion transport (51) and 
water transport (44). Using a microarray analysis of ge-
nes differentially expressed in the efferent ductules of 
fulvestrant-treated animals, we have been able to iden-
tify a significant impact of the antiestrogen treatment 
on gene expression, and besides genes related to ion 
and water transport, genes related to extracellular ma-
trix organization and sperm maturation and/or capa-
citation, among others, were also affected, suggesting 
a broader role of estrogen to regulate the morphology 
and function of the efferent ductules (52).  
epididymis
The epididymis is a key organ for the maturation of 
sperm. Its function is controlled by several hormones 
and growth factors and testosterone is recognized as 
a primary stimulus for epididymal development and 
sperm maturation. The mammalian epididymis is a 
segmented organ comprised of a single, highly coiled 
tubule, conventionally divided into caput, corpus and 
cauda regions (53). 
Although the main source of estrogen in the male 
is the testis, it has been suggested more recently that 
the epididymis is also capable of estrogen biosynthe-
sis. The P450 aromatase and the 17β-hydroxysteroid 
dehydrogenase I mRNA are present in the caput and 
cauda of rat epididymis (7). The estrogen sulfotrans-
ferase, which produces sulfated estrogens that do not 
bind to ESRs, is highly expressed along the bovine epi-
didymis (54). ESR1 is expressed in the epididymis of 
several species (55), where it seems to participate in the 
regulation of narrow cells of the initial segment of the 
epididymis and clear cells in the remaining segments. In 
the bonnet monkey, ESR1 and ESR2 are expressed in 
Estrogen in the male reproductive system
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Figure 1. Morphological changes in the efferent ductules of animals treated with the antiestrogen fulvestrant (10 mg/animal, once a week, for two months, subcutaneously). Note 
the dilation of the lumen of the ductules and the reduced highness of the epithelial layer in animals treated with the antiestrogen (B), compared to control animals (A). No significant 
morphological changes were observed in the efferent ductules removed from animals treated with the aromatase inhibitor anastrozole (0.1 mg/kg, daily, during one month, orally) 
compared to control (C and D, respectively). Representative photomicrographies of cross sections of efferent ductules stained with hematoxylin-eosin. Scale bar 100 µm.
A
C
B
D
all three regions of the epididymis (56), in contrast to 
other primates, in which expression levels are very low 
(26). In the boar, ESR2 is localized in the principal and 
basal cells of all three epididymal regions, and ESR1 
was localized in the principal cells of the caput, some 
cells of the corpus and was not present in the cauda 
(57). In the rat, Atanassova and cols. (58) showed that 
the expression of ESR1 varied with age. On day 10 and 
on days 25-35, the epithelial expression of ESR1 was 
absent, but it was detectable on day 18 in epithelial cells 
in the caput, corpus and proximal cauda. In contrast, 
ESR2 expression was immunolocalized to epithelial 
and some stromal cells at all ages (58).
The role of estrogen in epididymal function is still 
not completely understood (55). In contrast with the 
dramatic effect on the efferent ductules, the Esr1-/- ani-
mal does not present significant alterations on epidi-
dymis morphology (9). Nevertheless, treatment of ani-
mals with estrogens or reduction of the endogenous 
estrogen seem to affect the development or function 
of the epididymis. It has been shown that reduction of 
the endogenous estrogen by treatment with an aroma-
tase inhibitor delayed epididymal development in boars 
(57). The gestational exposure of rats to diethylstilbes-
trol decreased expression of the AR mRNA and stimu-
lated the ESR1 mRNA in the offspring (59). Exposure 
of adult male rats to dietary phytoestrogens reduced 
fecundity, and increased ESR1 and AR mRNA in the 
initial segment, but decreased them in the cauda of the 
epididymis (60). A microarray analysis of the effects of 
the antiestrogen fulvestrant on gene expression in the 
epididymis of the bonnet monkey has demonstrated 
that the expression of several genes involved in fluid ab-
sorption is affected by the treatment, including a reduc-
tion in aquaporin 1 and NHE3 expression (61). Tre-
atment of mice with the antiestrogen fulvestrant (ICI 
182,780) induced capping and vesiculation of narrow 
cells in the initial segment, accumulation of PAS-positi-
ve granules in apical cells of the caput of the epididymis, 
an increase in lysosomal granules in clear cells of the 
corpus and cauda, and a decrease in the concentration 
of cauda sperm, progressive sperm motility and a decre-
Estrogen in the male reproductive system
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ase in fertility (55). In the male rat, treatment with the 
nonsteroidal type I selective estrogen receptor modula-
tor (SERM) tamoxifen induced alterations in testis and 
epididymis that seem to be responsible for a decrease in 
sperm concentration and motility (62). Estrogen may 
also be involved in the ejaculatory process, regulating 
the contractile activity of the rabbit epididymis during 
semen emission (63).  
Vas deferens
Although the literature refers that, in most species, 
ESR2 but not ESR1 is present in the epithelium of the 
vas deferens (3), using real time PCR we have been able 
to detect the mRNA for both receptors, as well as for 
the GPER in the vas deferens of adult rats (64). Using 
immunohistochemistry study in vas deferens from rats 
at different ages, Atanassova and cols. (58) showed that 
the expression of ESR1 changed with age and it was 
confined to a band of periductal stromal cells in animals 
from 18-35 days, but it was absent in adult animals. 
The expression of ESR1 in stromal cells in the vas defe-
rens contrasts with the predominantly epithelial immu-
noexpression in the epididymis of 18-day old rats. On 
the other hand, expression of ESR2 was detected at all 
ages (58). Chronic prostatitis and epithelial abnormali-
ties in the vas deferens were observed in newborn Spra-
gue-Dawley male rats, treated from days 1-5 with two 
SERMs, tamoxifen and toremifene or two estrogens, 
ethinylestradiol and diethylstilbestrol. These changes 
involved hyperplasia and development of subepithelial 
glandular structures of vas deferens (65). In a previous 
study, Atanassova and cols. (66) had already reported 
stromal and epithelial abnormalities in the vas deferens 
and cauda epididymis, in adult rats treated neonatally 
with diethylstilbestrol, which were related to a delay 
in the development of basal cells. These abnormalities 
included: coiling of the normally straight initial vas de-
ferens, gross epithelial alterations, widening of the pe-
riductal non-muscle layer, infiltration of the immune 
cells across the epithelium to the lumen, and reduc-
tion or absence of sperm from the vas deferens lumen. 
All together, these observations suggest that estrogen 
may be important to determine the development of 
a normal epithelium and stroma of the vas deferens. 
Whether estrogen is also involved in other functions of 
the organ, such as regulation of absorptive function or 
secretion of proteins, still remains to be determined. 
prostate
Studies using different experimental approaches have 
revealed that estrogens play an essential role in the nor-
mal development and function of the prostate, and in 
the etiology of prostatic diseases (5,6). Direct effects of 
estrogen on the prostate are mediated through ESR1 
and ESR2 (5,6). 
ESR1 is primarily localized to the stromal cells of 
the adult prostate in men, dogs, monkeys and rodents 
(5,6). Studies in rodent prostate have shown a high 
percentage of stromal cells expressing ESR1 (mRNA 
and protein) throughout prenatal morphogenesis, and 
that this proportion significantly declines thereafter, 
which suggests a specific role for ESR1 in the prostate 
development (5,6). On the other hand, after estrogen 
exposure, it is possible to detect this receptor in the 
epithelium (67). The close proximity of ESR1-positive 
stromal cells to epithelial cells allows possible paracrine 
effects of estrogens on the prostate epithelium. In fact, 
studies using mice with disruption of ESRs (Esr1-/- and 
Esr2-/- mice) have shown that ESR1 mediates estradiol-
induced squamous metaplasia in the prostate (67). 
Moreover, recent studies have demonstrated that ESR1 
acts through a paracrine mechanism to regulate prosta-
tic branching morphogenesis, and is involved in prolife-
ration and differentiation of prostatic stromal compart-
ment (68). Recently, prostatic hormonal carcinogenesis 
has been shown to be mediated by in situ estrogen pro-
duction and ESR1 signaling (69).
In humans, ESR1 has also been observed in stromal 
cells during fetal development (5,6). However, while 
one study shows ESR1 protein only in stromal cells, 
other demonstrates the presence of ESR1 in fetal pros-
tatic utricle and periurethral epithelium during mid-to-
late gestation. Squamous metaplasia is directly associa-
ted with epithelial ESR1 in the periurethral ducts and 
stromal ESR1 in the peripheral prostatic acini. There is 
evidence that estrogens acting through stromal ESR1 
may contribute at some level to the etiology of the 
most prevalent prostatic diseases, including chronic 
prostatitis, benign prostatic hyperplasia (BPH), and 
carcinogenesis and cancer progression (6).
In the rat and murine prostate, ESR2 (mRNA and 
protein) is mainly localized to differentiated luminal epi-
thelial cells (5,6). Expression of ESR2 is low at birth, 
increases as epithelial cells differentiate, and reaches its 
maximum with the onset of secretory capacity at puberty, 
which suggests a role for ESR2 in the differentiated func-
tions of the rat prostate. Furthermore, Esr2-/- mice show 
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hyperproliferative prostatic epithelium and altered cellular 
differentiation, with accumulation of basal-intermediary 
cells. It has also been suggested that the anti-proliferative 
effect mediated by ESR2 could function as a brake for the 
androgenic stimulation of prostate growth. Nevertheless, 
conflicting results about the role of ESR2 in prostate pro-
liferation have been observed among the different studies 
using Esr2-/- mice. While epithelial hyperplasia with in-
creased BrdU labeling has been shown in prostate from 
Esr2-/- mice, other studies using this same model or a di-
fferent Esr2-/- model presented different results (5).
The development pattern for ESR2 in the human 
prostate differs from the rodent (5). ESR2 is expressed 
throughout the urogenital sinus epithelium and stroma 
in early fetal development and this expression is main-
tained in most epithelial and stromal cells throughout 
the gestation, suggesting the involvement of ESR2 and 
estrogens in morphogenesis and differentiation of the 
prostate. While this pattern is maintained postnatally 
for several months, ESR2 expression decreases in adlu-
minal cells at puberty. While some studies have shown 
the expression of ESR2 in basal epithelial cells, with 
lower stromal expression, other have shown high ex-
pression of ESR2 in both basal and luminal epithelial 
cells of the adult human prostate.
Prostatic epithelial ESR2 may play a role as pro-di-
fferentiation, anti-proliferative, anti-inflammatory and 
as an inducer of anti-oxidant genes. The loss of ESR2 
may contribute to prostate cancer progression in organ 
confined disease, and the strong reemergence of ESR2 
at metastatic sites implicates a potential role in andro-
gen-independent progression (5,6). Thus, although 
ESR2 is the predominant ESR expressed in the adult 
prostate, its role has not yet been clearly established.
Estrogens have also been shown to act synergisti-
cally with androgens to induce BPH in dogs (70), and 
prostatic cancer in adult Noble rats (71,72). Although 
the mechanism of estrogen action in the prostate has 
received attention for more than two decades, it is still 
poorly understood. Cross-talk among the receptors of 
the nuclear steroid receptor family might also occur in 
the prostate, and the regulation of AR, ESR1 and ESR2 
during prostate development, maturation and carcino-
genesis remains as an important research area. In prima-
ry cultured human prostate stromal cells and prostate 
stromal cell line WPMY-1, recent studies showed that 
17β-estradiol activates ERK pathway and cell prolifera-
tion through rapid signaling of ESR1 and that GPER is 
not involved in these processes (73). A recent study from 
our laboratory showed that the treatment of rats with the 
antiestrogen fulvestrant induces a decrease on ERK1/2 
figure 2 phosphorylation and prostatic cell proliferation 
(unpublished data). Figure 2 summarizes the effects of 
17β-estradiol via ESR1 and ESR2 in rat prostate.
Figure 2. Cross section of rat ventral prostate stained with Masson’s trichrome. Schematic representation of the local estrogen signaling mechanisms. Testosterone is locally 
metabolized to 17β-estradiol (E2) by aromatase, and acts via ESR1 and ESR2. Testosterone is also metabolized to DHT (5α-dihydrotestosterone) by 5α-reductase. DHT is 
metabolized to 3β-Adiol (5α-androstane-3β, 17β-diol) by 3β-hydroxysteroid oxidoreductase, and acts via ESR2. The effects of 17β-estradiol via ESR1 in the stroma and 
epithelia include proliferation, differentiation and carcinogenesis. Estrogen action via ESR2 may modulate differentiation, among other possible actions. The antiproliferative 
effect of ESR2 remains to be better determined. Scale bar 15 mm.
Testosterone DHT 3β-Adiol5α-redutase 3β-HSD
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These findings provide a fundamental basis for fu-
ture studies to determine the physiological roles of es-
trogen in the ventral prostate and for new approaches 
in prostatic diseases, such as benign prostate hyperpla-
sia and prostatic cancer. It is possible that ESR-specific 
agonists and antagonists may provide the most benefi-
cial therapeutic strategies in future clinical trials.
concluDIng remArKs
Cellular and physiological roles of ESRs and GPER are 
becoming better defined for tissues of the male repro-
ductive system. In this review, we have discussed the 
advances in knowledge about the localization, mole-
cular signaling and function of these receptors. The 
results obtained in our laboratory and those from the 
literature support the concept that estrogens play an 
important role in modulating the function of the male 
reproductive tract throughout the species. Furthermo-
re, estrogens play a role in (in)fertility and carcinoge-
nesis. The use of selective ligands, siRNA approaches 
and knockout animals will certainly enhance our un-
derstanding on the role of each receptor in the male 
reproductive function.
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